1. Home
  2. NRIX vs LEG Comparison

NRIX vs LEG Comparison

Compare NRIX & LEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

N/A

Current Price

$15.88

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Logo Leggett & Platt Incorporated

LEG

Leggett & Platt Incorporated

N/A

Current Price

$11.39

Market Cap

1.6B

ML Signal

N/A

Company Overview

Basic Information
Metric
NRIX
LEG
Founded
2009
1883
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Home Furnishings
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
2020
2017

Fundamental Metrics

Financial Performance
Metric
NRIX
LEG
Price
$15.88
$11.39
Analyst Decision
Strong Buy
Hold
Analyst Count
13
4
Target Price
$29.46
$10.50
AVG Volume (30 Days)
844.9K
1.8M
Earning Date
05-01-2026
05-12-2026
Dividend Yield
N/A
1.76%
EPS Growth
N/A
N/A
EPS
N/A
1.51
Revenue
$76,987,000.00
$5,203,900,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$29.30
$4.41
P/E Ratio
N/A
$7.55
Revenue Growth
99.31
1.37
52 Week Low
$8.18
$6.48
52 Week High
$22.50
$13.00

Technical Indicators

Market Signals
Indicator
NRIX
LEG
Relative Strength Index (RSI) 42.26 42.85
Support Level $15.62 $10.89
Resistance Level $19.98 $11.94
Average True Range (ATR) 0.78 0.51
MACD -0.03 -0.14
Stochastic Oscillator 36.46 11.78

Price Performance

Historical Comparison
NRIX
LEG

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About LEG Leggett & Platt Incorporated

Leggett & Platt Inc designs and produces engineered components and products found in homes and automobiles. It operates its business through three segments namely Bedding Products, Specialized Products, and Furniture, Flooring, and Textile Products. It generates the majority of its revenue from Bedding Products. Serving a broad suite of customers around the world, Leggett & Platt's products include bedding components, automotive seat support, and lumbar systems, specialty bedding foam and private label finished mattresses, components for home furniture, and work furniture, flooring underlayment, adjustable beds, and various other products.

Share on Social Networks: